ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2773

Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88

Keith A. Sikora1, Joshua R. Bennett2, Laurens Vyncke3, Zuoming Deng4, Wanxia Li Tsai2, Ewald Pauwels5, Gerlinde Layh-Schmitt2, April D. Brundidge2, Fatemeh Navid2, Kristien Zaal6, Eric Hanson2, Massimo G. Gadina7, Louis M. Staudt8, Thomas A. Griffin9, Jan Tavernier3, Frank Peelman3 and Robert Colbert2, 1Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3Department of Biochemistry, Ghent University, Ghent, Belgium, 4Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5Center for Molecular Modeling, Ghent University, Ghent, Belgium, 6Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 7Translational Immunology, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 8National Cancer Institute, National Institutes of Health, Bethesda, MD, 9Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Autoinflammatory Disease, Genetic disorders, juvenile idiopathic arthritis (JIA), neutrophils and osteoclastogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Innate Immunity and Rheumatic Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Using whole exome sequencing, we discovered a de novo heterozygous germline mutation in MYD88 (myeloid differentiation primary response 88) (c.666T>G, p.S222R) in a child with destructive small-to-medium joint polyarticular juvenile arthritis (JA) exhibiting persistent neutrophil-predominant synovial infiltrates and rash. MyD88 is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-κB. Germline loss-of-function mutations in MyD88 cause immunodeficiency, while somatic gain-of-function mutations have been linked to lymphoma. We asked whether the MyD88 S222R mutation causes gain-of-function effects that could contribute to the development of destructive arthritis.

Methods: The patient was evaluated for peripheral blood immunophenotype, cytokine and chemokine production, and monocyte osteoclastogenesis, compared to family and other healthy controls. Functional studies in monocytes and dermal fibroblasts included gene/protein expression, quantitation of neutrophil chemotaxis, and siRNA-mediated knockdown of MyD88 and p65. Wild type (WT) or S222R MyD88-AU1 fusion proteins were re-expressed in MyD88-deficient THP-1 cells. NF-κB activity was measured via p65 subunit phosphorylation and using a reporter system. Effects on MyD88 structure were predicted via molecular dynamics modeling, and mechanistic studies were performed to assess the capacity of S222R MyD88 to oligomerize, which is necessary for signaling, using IF microscopy and proximity ligation assay (PLA).

Results: MyD88 S222R results in increased NF-κB p65 phosphorylation and NF-κB reporter activity in THP-1 cells compared to WT MyD88. IF microscopy and PLA demonstrated increased MyD88-S222R oligomerization compared to WT MyD88, indicating a behavior similar to MyD88-L265P, which is the most common lymphoma-associated MyD88 gain-of-function mutation. Immunophenotyping showed a persistent absence of CD16 on monocytes, an expansion of CD4+ Th17 T cells, and the presence of a previously uncharacterized CD123+CD11c+ dendritic cell population, as well as markedly increased basal and stimulated p-STAT3 in monocytes and T and B lymphocytes in the patient. Peripheral monocytes exhibited baseline interferon and chemokine gene expression signatures, while monocyte-derived osteoclasts exhibited enhanced survival and were morphologically larger than those cultured from a control. Fibroblasts exhibited significantly greater baseline expression of CXCL chemokines compared to controls, which abated upon MyD88 or p65 knockdown.

Conclusion: This is the first description of a de novo germline MyD88 mutation (S222R) associated with severe polyarticular JA. We demonstrate clear gain-of-function effects of the S222R mutation using THP-1 cells which are consistent with biologic effects in hematopoietic and non-hematopoietic cells derived from the patient, and likely to be a consequence of increased oligomerization. These effects offer plausible mechanisms for neutrophil-predominant, destructive arthritis, and support a role for single gene defects contributing to extreme JA phenotypes.


Disclosure: K. A. Sikora, None; J. R. Bennett, None; L. Vyncke, None; Z. Deng, None; W. L. Tsai, None; E. Pauwels, None; G. Layh-Schmitt, None; A. D. Brundidge, None; F. Navid, None; K. Zaal, None; E. Hanson, None; M. G. Gadina, None; L. M. Staudt, None; T. A. Griffin, None; J. Tavernier, None; F. Peelman, None; R. Colbert, None.

To cite this abstract in AMA style:

Sikora KA, Bennett JR, Vyncke L, Deng Z, Tsai WL, Pauwels E, Layh-Schmitt G, Brundidge AD, Navid F, Zaal K, Hanson E, Gadina MG, Staudt LM, Griffin TA, Tavernier J, Peelman F, Colbert R. Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88 [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/severe-juvenile-arthritis-associated-with-a-de-novo-gain-of-function-germline-mutation-in-myd88-3/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/severe-juvenile-arthritis-associated-with-a-de-novo-gain-of-function-germline-mutation-in-myd88-3/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology